Advances in pathophysiology and therapeutic drugs of heart failure with pre-served ejection fraction
Heart failure with preserved ejection fraction accounts for 40％-71％of heart failure,is amultisystem disease involving the heart,kidneys,lungs,vascular system and adipose tissue,and seriously affects patients'quality of life.Recently,with the continuous improvement of medical research,its clinical treatment has achieved certain effects,but the prognosis of patients is still poor,the recurrence rate is increased and the quality of life is decreased.This article reviews the recent domestic and foreign research reports on heart failure with preserved e-jection fraction,and finds that its pathological and physiological mechanisms are mainly related to hypertension,coronary artery disease and coronary microvascular dysfunction,left ventricular insufficiency,right ventricular dysfunction and pulmonary artery disease,abnormal hormone system,obesity,systemic inflammation and meta-bolic abnormality.Diuretics,renin-angiotensin-aldosterone system(RAAS)inhibitors,sodium-glucose cotrans-porter-2 inhibitor(SGLT2i),mineralocorticoid receptor antagonist and statins are usually used for treatment.The construction of animal models of different types is expected to provide some valuable references for the clinical di-agnosis and treatment of heart failure with preserved ejection fraction.
heart failure with preserved ejection fractionpathological and physiological mechanismsdrug therapyanimal model
万方数据
维普
